Tomographic Ultrasound Imaging in the Diagnosis of Breast Tumors under the Guidance of Deep Learning Algorithms

Le résumé fourni par la source

This study was aimed to discuss the feasibility of distinguishing benign and malignant breast tumors under the tomographic ultrasound imaging (TUI) of deep learning algorithm. The deep learning algorithm was used to segment the images, and 120 patients with breast tumor were included in this study, all of whom underwent routine ultrasound examinations. Subsequently, TUI was used to assist in guiding the positioning, and the light scattering tomography system was used to further measure the lesions. A deep learning model was established to process the imaging results, and the pathological test results were undertaken as the gold standard for the efficiency of different imaging methods to diagnose the breast tumors. The results showed that, among 120 patients with breast tumor, 56 were benign lesions and 64 were malignant lesions. The average total amount of hemoglobin (HBT) of malignant lesions was significantly higher than that of benign lesions (P < 0.05). The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of TUI in the diagnosis of breast cancer were 90.4%, 75.6%, 81.4%, 84.7%, and 80.6%, respectively. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of ultrasound in the diagnosis of breast cancer were 81.7%, 64.9%, 70.5%, 75.9%, and 80.6%, respectively. In addition, for suspected breast malignant lesions, the combined application of ultrasound and tomography can increase the diagnostic specificity to 82.1% and the accuracy to 83.8%. Based on the above results, it was concluded that TUI combined with ultrasound had a significant effect on benign and malignant diagnosis of breast cancer and can significantly improve the specificity and accuracy of diagnosis. It also reflected that deep learning technology had a good auxiliary role in the examination of diseases and was worth the promotion of clinical application.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.